Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib

Mariko Minami, Takeshi Arita, Hiromi Iwasaki, Tsuyoshi Muta, Takatoshi Aoki, Kenichi Aoki, Satoshi Yamasaki, Takamitsu Matsushima, Koji Kato, Katsuto Takenaka, Kazuki Tanimoto, Tomohiko Kamimura, Ryosuke Ogawa, Koichi Akashi, Toshihiro Miyamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib (n = 37), nilotinib (n = 30) or dasatinib (n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22·7 mmHg in the imatinib group, 23·1 mmHg in the nilotinib group and 23·4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19·0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2·7%) treated with imatinib, three (10·0%) with nilotinib and five (13·2%) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment.

Original languageEnglish
Pages (from-to)578-587
Number of pages10
JournalBritish Journal of Haematology
Volume177
Issue number4
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Pulmonary Hypertension
Protein-Tyrosine Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Echocardiography
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Dasatinib
Dyspnea
Arterial Pressure
Therapeutics
Lung
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. / Minami, Mariko; Arita, Takeshi; Iwasaki, Hiromi; Muta, Tsuyoshi; Aoki, Takatoshi; Aoki, Kenichi; Yamasaki, Satoshi; Matsushima, Takamitsu; Kato, Koji; Takenaka, Katsuto; Tanimoto, Kazuki; Kamimura, Tomohiko; Ogawa, Ryosuke; Akashi, Koichi; Miyamoto, Toshihiro.

In: British Journal of Haematology, Vol. 177, No. 4, 01.05.2017, p. 578-587.

Research output: Contribution to journalArticle

Minami, M, Arita, T, Iwasaki, H, Muta, T, Aoki, T, Aoki, K, Yamasaki, S, Matsushima, T, Kato, K, Takenaka, K, Tanimoto, K, Kamimura, T, Ogawa, R, Akashi, K & Miyamoto, T 2017, 'Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib', British Journal of Haematology, vol. 177, no. 4, pp. 578-587. https://doi.org/10.1111/bjh.14608
Minami, Mariko ; Arita, Takeshi ; Iwasaki, Hiromi ; Muta, Tsuyoshi ; Aoki, Takatoshi ; Aoki, Kenichi ; Yamasaki, Satoshi ; Matsushima, Takamitsu ; Kato, Koji ; Takenaka, Katsuto ; Tanimoto, Kazuki ; Kamimura, Tomohiko ; Ogawa, Ryosuke ; Akashi, Koichi ; Miyamoto, Toshihiro. / Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. In: British Journal of Haematology. 2017 ; Vol. 177, No. 4. pp. 578-587.
@article{d2c46b4059bc476c82b5d7d3753f08d4,
title = "Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib",
abstract = "Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib (n = 37), nilotinib (n = 30) or dasatinib (n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22·7 mmHg in the imatinib group, 23·1 mmHg in the nilotinib group and 23·4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19·0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2·7{\%}) treated with imatinib, three (10·0{\%}) with nilotinib and five (13·2{\%}) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment.",
author = "Mariko Minami and Takeshi Arita and Hiromi Iwasaki and Tsuyoshi Muta and Takatoshi Aoki and Kenichi Aoki and Satoshi Yamasaki and Takamitsu Matsushima and Koji Kato and Katsuto Takenaka and Kazuki Tanimoto and Tomohiko Kamimura and Ryosuke Ogawa and Koichi Akashi and Toshihiro Miyamoto",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/bjh.14608",
language = "English",
volume = "177",
pages = "578--587",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib

AU - Minami, Mariko

AU - Arita, Takeshi

AU - Iwasaki, Hiromi

AU - Muta, Tsuyoshi

AU - Aoki, Takatoshi

AU - Aoki, Kenichi

AU - Yamasaki, Satoshi

AU - Matsushima, Takamitsu

AU - Kato, Koji

AU - Takenaka, Katsuto

AU - Tanimoto, Kazuki

AU - Kamimura, Tomohiko

AU - Ogawa, Ryosuke

AU - Akashi, Koichi

AU - Miyamoto, Toshihiro

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib (n = 37), nilotinib (n = 30) or dasatinib (n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22·7 mmHg in the imatinib group, 23·1 mmHg in the nilotinib group and 23·4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19·0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2·7%) treated with imatinib, three (10·0%) with nilotinib and five (13·2%) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment.

AB - Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib (n = 37), nilotinib (n = 30) or dasatinib (n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22·7 mmHg in the imatinib group, 23·1 mmHg in the nilotinib group and 23·4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19·0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2·7%) treated with imatinib, three (10·0%) with nilotinib and five (13·2%) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment.

UR - http://www.scopus.com/inward/record.url?scp=85016417259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016417259&partnerID=8YFLogxK

U2 - 10.1111/bjh.14608

DO - 10.1111/bjh.14608

M3 - Article

C2 - 28340283

AN - SCOPUS:85016417259

VL - 177

SP - 578

EP - 587

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -